Agilent Technologies, Inc. (NYSE:A) Shares Sold by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI reduced its stake in shares of Agilent Technologies, Inc. (NYSE:AFree Report) by 8.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,955 shares of the medical research company’s stock after selling 182 shares during the period. Parsons Capital Management Inc. RI’s holdings in Agilent Technologies were worth $272,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Agilent Technologies in the 4th quarter valued at about $393,291,000. Victory Capital Management Inc. boosted its holdings in shares of Agilent Technologies by 939.8% in the 3rd quarter. Victory Capital Management Inc. now owns 2,296,512 shares of the medical research company’s stock valued at $256,796,000 after buying an additional 2,075,649 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Agilent Technologies by 233.7% in the 4th quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock valued at $370,552,000 after buying an additional 1,867,377 shares during the period. Morgan Stanley boosted its stake in Agilent Technologies by 79.4% during the 4th quarter. Morgan Stanley now owns 4,145,767 shares of the medical research company’s stock valued at $620,414,000 after purchasing an additional 1,835,413 shares during the period. Finally, Meritage Group LP acquired a new position in Agilent Technologies during the 3rd quarter valued at about $184,437,000.

Agilent Technologies Stock Down 0.3 %

A stock opened at $143.73 on Thursday. Agilent Technologies, Inc. has a 52-week low of $96.80 and a 52-week high of $151.58. The company’s 50 day simple moving average is $139.08 and its 200-day simple moving average is $127.25. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The firm has a market capitalization of $42.12 billion, a P/E ratio of 34.22, a P/E/G ratio of 4.41 and a beta of 1.11.

Agilent Technologies (NYSE:AGet Free Report) last released its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The business had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the previous year, the business earned $1.37 earnings per share. The firm’s revenue was down 5.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.51 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be given a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s payout ratio is presently 22.38%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on A. Citigroup boosted their target price on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. boosted their target price on shares of Agilent Technologies from $140.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Bank of America lowered shares of Agilent Technologies from a “buy” rating to a “neutral” rating and boosted their target price for the company from $130.00 to $133.00 in a research note on Tuesday, December 12th. Oppenheimer boosted their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Finally, The Goldman Sachs Group boosted their target price on shares of Agilent Technologies from $128.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, December 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.29.

View Our Latest Analysis on A

Insider Activity at Agilent Technologies

In related news, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $149.00, for a total transaction of $719,372.00. Following the transaction, the vice president now directly owns 21,329 shares in the company, valued at $3,178,021. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.